Table 2 CpGs that possess the strongest associations between methylation levels and development of invasive ductal carcinoma

cg15786837

17

46806935

HOXB13

TSS1500

1.86 (1.37–2.53)

6.97E-05

cg22030072

2

119603673

EN1

Body

3.61 (1.90–6.88)

9.54E-05

cg13604794

17

48050338

DLX4

Body

1.92 (1.37–2.69)

1.47E-04

cg18944010

1

119522855

TBX15

5′UTR

2.12 (1.43–3.15)

1.88E-04

cg01002529

3

69591807

2.35 (1.50–3.70)

2.23E-04

cg08261841

7

142982463

TMEM139

5′UTR

0.56 (0.41–0.77)

2.82E-04

cg02926307

12

106520198

NUAK1

Body

0.40 (0.25–0.67)

3.60E-04

cg05075579

11

121421206

SORL1

Body

3.60 (1.77–7.30)

3.99E-04

cg15350661

12

322641

SLC6A12

5′UTR

2.31 (1.45–3.70)

4.10E-04

cg02770983

11

31822341

PAX6

Body

2.11 (1.39–3.19)

4.66E-04

cg00232535

7

5593287

0.47 (0.30–0.72)

4.79E-04

cg18343474

1

229566908

1.93 (1.33–2.80)

4.87E-04

cg00725138

22

19716556

0.50 (0.34–0.74)

5.34E-04

cg03695909

X

47346601

0.30 (0.15–0.59)

5.49E-04

cg26236177

14

61110649

1.77 (1.28–2.44)

5.60E-04

cg13434989

13

78493305

EDNRB

TSS1500

1.83 (1.30–2.58)

5.67E-04

cg24006505

6

41337238

1.95 (1.33–2.58)

6.04E-04

cg04636194

X

49594154

PAGE4

5′UTR

0.43 (0.27–0.70)

6.07E-04

cg23429749

14

102050815

0.47 (0.31–0.73)

6.12E-04

cg05231018

17

46806763

HOXB13

TSS1500

1.70 (1.25–2.29)

6.18E-04

cg02492708

16

2005062

RPL3L

TSS1500

0.50 (0.34–0.75)

6.24E-04

cg21211271

1

6265071

RNF207

TSS1500

2.37 (1.44–3.90)

6.48E-04

cg16009714

17

70241415

3.48 (1.70–7.12)

6.60E-04

cg00321709

10

135341933

CYP2E1

Body

2.04 (1.35–3.08)

6.69E-04

cg20401252

2

5834062

SOX11

1stExon

1.90 (1.31–2.73)

6.70E-04

cg19827511

14

93580644

ITPK1

Body

0.56 (0.39–0.78)

6.86E-04

cg10827488

11

113953838

ZBTB16

Body

3.42 (1.68–6.96)

6.97E-04

cg04327247

9

100564659

0.50 (0.34–0.75)

7.84E-04

cg26511386

7

142982262

TMEM139

5′UTR

0.52 (0.36–0.76)

8.02E-04

cg00332067

12

55004429

GLYCAM1

TSS200

2.10 (1.36–3.24)

8.30E-04